Provided by Tiger Trade Technology Pte. Ltd.

Sana Biotechnology, Inc.

3.14
+0.02000.64%
Volume:287.17K
Turnover:893.71K
Market Cap:836.39M
PE:-3.26
High:3.18
Open:3.14
Low:3.08
Close:3.12
52wk High:6.55
52wk Low:1.42
Shares:266.37M
Float Shares:168.00M
Volume Ratio:0.76
T/O Rate:0.17%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9636
EPS(LYR):-0.9642
ROE:-118.70%
ROA:-26.00%
PB:5.20
PE(LYR):-3.26

Loading ...

Sana Biotechnology files Form 3; EVP and Chief Scientific Officer Dhavalkumar Dhirajlal Patel reports 99,510 common shares owned directly

Reuters
·
Mar 28

BUZZ - US STOCKS ON THE MOVE-Kyivstar Group, Applied Materials, Tevogen Bio

Reuters
·
Mar 14

Durable HIP Technology Data De‑Risks Sana Biotechnology’s SC451 Program and Supports Buy Rating

TIPRANKS
·
Mar 14

BUZZ-Sana Biotechnology rises as cell transplant shows promise in type 1 diabetes treatment

Reuters
·
Mar 13

Sana announces follow-up results from first-in-human study transplanting UP421

TIPRANKS
·
Mar 13

Sana reports positive 14-month results from UP421 hypoimmune islet transplant study in type 1 diabetes

Reuters
·
Mar 13

Sana Biotechnology Inc - Hip-Modified Islets Show Safety, Immune Evasion, and Insulin Production at 14 Months

THOMSON REUTERS
·
Mar 13

Sana Biotechnology Inc - No Safety Issues Identified in up421 Islet Cell Study

THOMSON REUTERS
·
Mar 13

Sana Biotechnology Inc - Expects to File Ind and Initiate Phase 1 Trial for Sc451 This Year

THOMSON REUTERS
·
Mar 13

Sana Biotechnology: Advancing T1D and In Vivo CAR-T Programs with 2026 Catalysts and Solid Cash Runway Supporting Buy Rating

TIPRANKS
·
Mar 07

Stock Track | Sana Biotechnology Plummets 5.24% Intraday on AI Adoption Risk Disclosure

Stock Track
·
Mar 05

AI Adoption Exposes Sana Biotechnology to Rising Data, Compliance, and Reputational Risks

TIPRANKS
·
Mar 05

Stock Track | Sana Biotechnology Plummets 5.09% Intraday After H.C. Wainwright Cuts Price Target

Stock Track
·
Mar 04

Sana Biotechnology Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Mar 04

Sana Biotechnology: Emerging Clinical Validation and 2026 Pivotal Milestones Underpin Buy Rating

TIPRANKS
·
Mar 04

Sana Biotechnology, Inc. : H.c. Wainwright Cuts Target Price to $7 From $9

THOMSON REUTERS
·
Mar 04

BRIEF-Sana Biotechnology Files For Mixed Shelf Size Not Disclosed - SEC Filing

Reuters
·
Mar 04

Sana Biotechnology Q4 adjusted EPS misses estimates

Reuters
·
Mar 04

Sana Biotechnology Updates ATM Program to Support Development

TIPRANKS
·
Mar 04

Sana Biotechnology Q4 Adj. EPS $(0.16) Misses $(0.13) Estimate

Benzinga
·
Mar 04